Success Metrics

Clinical Success Rate

100.0%

Based on 11 completed trials

Completion Rate

100%(11/11)

Active Trials

0(0%)

Results Posted

18%(2 trials)

Phase Distribution

Ph phase_3

14%

Ph early_phase_1

Ph phase_1

14%

Ph phase_4

14%

Ph phase_2

50%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution14 total trials

Early Phase 1First-in-human

1(7.1%)

Phase 1Safety & dosage

2(14.3%)

Phase 2Efficacy & side effects

7(50.0%)

Phase 3Large-scale testing

2(14.3%)

Phase 4Post-market surveillance

2(14.3%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

100.0%

11 of 11 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Completed(11)

Other(3)

Detailed Status

Completed11

unknown3

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

100.0%

Most Advanced

Phase 4

Trials by Phase

Early Phase 11 (7.1%)

Phase 12 (14.3%)

Phase 27 (50.0%)

Phase 32 (14.3%)

Phase 42 (14.3%)

Trials by Status

unknown321%

completed1179%

Recent Activity

0 active trials

Showing 5 of 14

completedphase_4

Selegiline for the Treatment of Excessive Daytime Sleepiness in Parkinson's Disease

NCT04870372

unknownphase_2

Clinical Trial of Selegiline Plus Docetaxel for the Treatment of Metastatic, Castrate-resistant Prostate Adenocarcinoma

NCT04586543

unknownphase_4

Clinical Trials (14)

Showing 14 of 14 trials

NCT04870372Phase 4

Selegiline for the Treatment of Excessive Daytime Sleepiness in Parkinson's Disease

Completed

NCT04586543Phase 2

Clinical Trial of Selegiline Plus Docetaxel for the Treatment of Metastatic, Castrate-resistant Prostate Adenocarcinoma

Unknown

NCT02225548Phase 4

Sagene 2014 - Parkinson's Disease and Erectile Dysfunction

Unknown

NCT00000336Phase 2

Selegiline in Outpatient Treatment for Cocaine Dependence - 1

Completed

NCT00032929Phase 3

Selegiline Transdermal System for the Treatment of Cocaine Dependence - 1

Completed

NCT00000201Phase 2

Pharmacological Modulation of Cocaine Effects - 1

Completed

NCT00000337Phase 1

Infusion Laboratory: Protocol 1 - Selegeline - 2

Completed

NCT00033072Phase 1

Assessment of Potential Interactions Between Methamphetamine and Selegiline - 1

Unknown

NCT01330030Phase 2

Selegiline Patch for Treatment of Nicotine Dependence

Completed

NCT01912391Phase 3

Clinical Research Study to Evaluate Selegiline in the Treatment of Borderline Personality Disorder

Completed

NCT00000188Phase 2

Selegiline in Treatment of Cocaine Dependence - 2

Completed

NCT00129311Phase 2

Usefulness of Selegiline as an Aid to Quit Smoking - 1

Completed

NCT01495195Phase 2

Combined Donepezil and Selegiline Effects on Cocaine-Reinforced Behavior

Completed

NCT00456976Early Phase 1

Efficacy of Selegiline in Negative Symptoms of Schizophrenia

Completed

All 14 trials loaded

Drug Details

Intervention Type: DRUG
Total Trials: 14